Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3058% above fair value
$7.05−0.23 (-3.16%)
Close on Nov 17, 2026Market cap $194.59MP/E –Yield –
Precision BioSciences total assets
Total assets on the balance sheet at the end of each period.
Precision BioSciences's total assets was $125.92M at Jun 30, 2026. For fiscal 2025 it was $154.42M, up 13.2% from the year before. The highest annual figure on record is $238.17M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.42M | +13.2% |
| FY2024 | Dec 31, 2024 | $136.39M | -14.6% |
| FY2023 | Dec 31, 2023 | $159.78M | -32.9% |
| FY2022 | Dec 31, 2022 | $238.17M | +12.6% |
| FY2021 | Dec 31, 2021 | $211.50M | +40.9% |
| FY2020 | Dec 31, 2020 | $150.16M | -36.2% |
| FY2019 | Dec 31, 2019 | $235.23M | +69.7% |
| FY2018 | Dec 31, 2018 | $138.60M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $125.92M | +15.6% |
| Q1 FY2026 | Mar 31, 2026 | $143.89M | +15.7% |
| Q4 FY2025 | Dec 31, 2025 | $154.42M | +13.2% |
| Q3 FY2025 | Sep 30, 2025 | $93.51M | -39.0% |
| Q2 FY2025 | Jun 30, 2025 | $108.93M | -34.3% |
| Q1 FY2025 | Mar 31, 2025 | $124.41M | -32.7% |
| Q4 FY2024 | Dec 31, 2024 | $136.39M | -14.6% |
| Q3 FY2024 | Sep 30, 2024 | $153.26M | -6.7% |
| Q2 FY2024 | Jun 30, 2024 | $165.80M | -8.7% |
| Q1 FY2024 | Mar 31, 2024 | $184.74M | -9.7% |
| Q4 FY2023 | Dec 31, 2023 | $159.78M | -32.9% |
| Q3 FY2023 | Sep 30, 2023 | $164.34M | -39.5% |
| Q2 FY2023 | Jun 30, 2023 | $181.70M | -38.9% |
| Q1 FY2023 | Mar 31, 2023 | $204.50M | +12.8% |
| Q4 FY2022 | Dec 31, 2022 | $238.17M | +12.6% |
| Q3 FY2022 | Sep 30, 2022 | $271.73M | +19.6% |
| Q2 FY2022 | Jun 30, 2022 | $297.16M | +29.1% |
| Q1 FY2022 | Mar 31, 2022 | $181.35M | -30.9% |
| Q4 FY2021 | Dec 31, 2021 | $211.50M | +40.9% |
| Q3 FY2021 | Sep 30, 2021 | $227.20M | +34.7% |
| Q2 FY2021 | Jun 30, 2021 | $230.11M | +24.9% |
| Q1 FY2021 | Mar 31, 2021 | $262.32M | +22.5% |
| Q4 FY2020 | Dec 31, 2020 | $150.16M | -36.2% |
| Q3 FY2020 | Sep 30, 2020 | $168.69M | -35.2% |
| Q2 FY2020 | Jun 30, 2020 | $184.19M | -32.3% |
| Q1 FY2020 | Mar 31, 2020 | $214.20M | +28.4% |
| Q4 FY2019 | Dec 31, 2019 | $235.23M | +69.7% |
| Q3 FY2019 | Sep 30, 2019 | $260.30M | – |
| Q2 FY2019 | Jun 30, 2019 | $271.92M | – |
| Q1 FY2019 | Mar 31, 2019 | $166.80M | – |
| Q4 FY2018 | Dec 31, 2018 | $138.60M | – |
See a number that looks wrong?